查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1936350

軟糖維生素市場：全球產業分析、規模、佔有率、成長、趨勢和預測（2025-2032）

Gummy Vitamins Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2032
出版日期: | 出版商: Persistence Market Research | 英文 198 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

主要發現：

  • CGRP抑制劑市場規模（2025年預測）：59.73億美元
  • 預計市場規模（2032年）：114.286億美元
  • 全球市場成長率（2025年至2032年複合年成長率）：9.7%

研究範圍：CGRP抑制劑市場

抑鈣素基因相關胜肽（CGRP）抑制劑是主要用於預防和治療偏頭痛的創新標靶治療。 CGRP是一種神經肽，透過介導血管舒張和神經系統中的疼痛傳遞，在偏頭痛的病理生理過程中發揮核心作用。 CGRP抑制劑的作用機轉是透過阻斷CGRP受體或直接與CGRP配體結合，從而降低偏頭痛發作的頻率、嚴重程度和持續時間。

CGRP抑制劑市場包括單株抗體和小分子拮抗劑（俗稱「吉泮類」），可透過注射、口服和鼻內給藥途徑給藥。這些治療方法擴大用於治療對曲坦類藥物、 BETA阻斷劑和抗憂鬱症等傳統療法反應不佳的發作性偏頭痛和慢性偏頭痛患者。市場覆蓋範圍包括醫院、神經科診所、零售藥局和線上藥局，其應用推廣主要得益於公眾認知度的提高、醫保報銷機制的完善以及適應症範圍的擴大（例如叢集性頭痛和創傷後頭痛）。

市場成長要素：

受全球偏頭痛負擔日益加重的推動，全球CGRP抑制劑市場正經歷強勁成長。偏頭痛是全球導致殘障調整生命年（DALYs）損失的主要原因之一，影響全球超過10億人。診斷率的提高、疾病認知度的提升以及偏頭痛作為一種慢性神經系統疾病的認知，都顯著擴大了目標患者群體。

CGRP抑制劑展現的卓越臨床療效和安全性是成長要素的另一個關鍵因素。臨床試驗和真實世界數據一致表明，接受CGRP標靶治療的患者每月偏頭痛發作天數顯著減少，生活品質顯著提高。這些結果促使CGRP抑制劑被納入更新的臨床指南，並被主要神經病學組織認可為適用於特定患者群體的第一線預防性治療藥物。

監管支持也進一步推動了市場成長。過去幾年，包括美國食品藥物管理局（FDA）、歐洲藥品管理局（EMA）以及亞太地區監管機構在內的多個衛生部門已核准了多種CGRP抑制劑，其中包括新的口服和鼻腔製劑。快速的監管核准和適應症的擴大縮短了產品上市時間，並增強了醫生開立此類治療方法的信心。

藥物遞送方式的技術進步和創新也發揮關鍵作用。與注射型生物製藥相比，口服和鼻腔給藥的CGRP抑制劑具有更高的便利性、更好的患者依從性和更廣泛的可及性。此外，數位健康工具（例如偏頭痛追蹤應用程式和遠距神經病學平台）的日益普及，有助於早期診斷、個人化治療和長期疾病管理，從而間接促進CGRP抑制劑的應用。

市場限制：

儘管CGRP抑制劑市場成長前景強勁，但仍面臨許多挑戰。其中最大的限制因素之一是治療費用高昂，尤其是基於單株抗體的CGRP抑制劑。高昂的價格和長期治療的需求會限制病患的用藥，尤其是在中低收入國家和地區，這些地區的健保報銷政策更為嚴格。

報銷障礙和支付方限制仍然是多個醫療保健系統面臨的問題。在某些市場，CGRP抑制劑仍屬於二線或三線治療方案，患者只有在多種常規療法失敗後才能獲得此類藥物。這種階梯式治療要求可能導致治療啟動延遲和市場滲透率受限。

此外，對長期安全性的擔憂以及缺乏長期治療期間的真實世界數據，可能導致部分處方醫生和患者猶豫不決。儘管現有證據顯示該藥物具有良好的安全性，但仍需持續進行上市後監測和長期研究，以全面評估其風險獲益比，尤其是在年輕患者群體和合併其他疾病的患者中。

市場機會：

由於持續的創新、適應症的拓展和地理區域的擴張，CGRP抑制劑市場蘊藏著巨大的機會。其中最具前景的機會之一在於開發具有更高療效、更長給藥間隔和更佳安全性的新一代CGRP抑制劑。對聯合治療和偏頭痛生物學新標靶的研究有望進一步拓展治療選擇。

對口服和非注射療法的需求不斷成長是另一個重要機會。與生物製藥相比，小分子CGRP拮抗劑因其可擴展性、易於分銷和生產製程簡化等優勢，在新興市場尤其具有吸引力。隨著第一代CGRP抑制劑專利即將到期，生物相似藥和非專利處方藥的上市有望提高藥物的可及性和患者的用藥便利性。

亞太、拉丁美洲以及中東和非洲等新興市場蘊藏著巨大的成長潛力，這得益於龐大的未確診患者群體、不斷完善的醫療基礎設施以及人們對神經系統疾病日益成長的認知。與當地製藥公司建立策略夥伴關係、投資醫生教育以及採取靈活的定價策略，將是掌握這些機會的關鍵。

本報告解答的關鍵問題：

  • 推動全球CGRP抑制劑市場成長的關鍵因素是什麼？
  • 哪些藥物類型、給藥途徑和治療適應症正在影響藥物的採用趨勢？
  • 監管核准和更新的臨床指引如何影響市場動態？
  • CGRP抑制劑市場的主要參與者有哪些？他們正在採取哪些策略來鞏固其市場地位？
  • 重點區域的新興趨勢和長期成長前景如何？

目錄

第1章執行摘要

第2章 市場概覽

  • 市場範圍和定義
  • 市場動態
    • 促進要素
    • 抑制因素
    • 機會
    • 任務
    • 主要趨勢
  • 新冠疫情影響分析
  • 預測因子－相關性和影響

第3章 加值見解

  • 價值鏈分析
  • 主要市場參與者
  • 監管狀態
  • PESTLE分析
  • 波特五力分析
  • 消費行為分析

第4章 價格趨勢分析（2019-2032）

  • 按產品類型進行價格分析
  • 影響產品價格的關鍵因素
  • 區域價格和產品偏好

第5章 全球軟糖維生素市場展望

  • 市場規模分析與預測
    • 2019-2024年市場規模績效分析
    • 市場規模分析及預測（2025-2032年）
  • 全球軟糖維他命市場按產品類型展望
    • 2019-2024年按產品類型分類的市場規模表現分析
    • 依產品類型分類的市場規模分析及預測（2025-2032年）
      • 單味維他命軟糖
      • 綜合維他命軟糖
  • 按產品類型分類的市場吸引力分析
  • 全球軟糖維生素市場成分展望
    • 按原料分類的市場規模績效分析，2019-2024 年
    • 市場規模分析及預測（依來源分類），2025-2032年
      • 植物來源
      • 動物源性
  • 按原料進行市場吸引力分析
  • 全球軟糖維生素市場按最終用戶分類的展望
    • 按最終用戶分類的市場規模績效分析，2019-2024 年
    • 依最終用戶分類的市場規模分析及預測（2025-2032 年）
      • 孩子
      • 成人
  • 最終用戶市場吸引力分析
  • 全球軟糖維他命市場按包裝類型展望
    • 按包裝類型分類的市場規模表現分析（2019-2024 年）
    • 依包裝類型分類的市場規模分析及預測（2025-2032年）
      • 瓶子和罐子
      • 立式袋
      • 其他
  • 按包裝類型進行市場吸引力分析
  • 全球軟糖維生素市場按分銷管道展望
    • 2019-2024年按通路分類的市場規模績效分析
    • 依分銷管道分類的市場規模分析及預測（2025-2032年）
      • 大賣場/超級市場
      • 藥局和藥房
      • 便利商店
      • 專業保健食品店
      • 線上零售
      • 其他
  • 市場吸引力分析：分銷管道

6. 全球軟糖維生素市場區域展望

  • 2019-2024年區域市場規模表現分析
  • 市場規模分析及預測（依地區分類，2025-2032年）
    • 北美洲
    • 拉丁美洲
    • 歐洲
    • 東亞
    • 南亞和大洋洲
    • 中東和非洲
  • 按地區分類的市場吸引力分析

7. 北美軟糖維生素市場展望

8. 歐洲軟糖維生素市場展望

9. 東亞軟糖維生素市場展望

第10章 南亞和大洋洲軟糖維生素市場展望：

11. 拉丁美洲軟糖維生素市場展望

12. 中東和非洲軟糖維生素市場展望

第13章 競爭格局

  • 2024年市佔率分析
  • 市場結構
    • 按市場分類的競爭強度程度
    • 競爭對手儀錶板
  • 公司簡介（詳情 - 概述、財務狀況、策略、近期發展）
    • Nestle
    • Unilever
    • Pfizer Inc.
    • Amway
    • Bayer AG
    • Haleon plc
    • Herbalife
    • The Clorox Company
    • Church &Dwight Co., Inc.
    • Otsuka Pharmaceutical Co., Ltd.
    • TopGum Industries Ltd.
    • Santa Cruz Nutritionals
    • Blackmores
    • Novomins Nutrition
    • ZanonVitamec
    • Others

第14章附錄

簡介目錄
Product Code: PMRREP34121

Persistence Market Research has recently released a comprehensive report on the global CGRP Inhibitors Market. This report offers an in-depth analysis of key market dynamics, including growth drivers, emerging trends, opportunities, and challenges, while providing strategic insights into the evolving competitive landscape and future outlook of this rapidly expanding pharmaceutical market.

Key Insights:

  • CGRP Inhibitors Market Size (2025E): US$ 5,973.0 Mn
  • Projected Market Value (2032F): US$ 11,428.6 Mn
  • Global Market Growth Rate (CAGR 2025 to 2032): 9.7%

Scope of the Report: CGRP Inhibitors Market

Calcitonin Gene-Related Peptide (CGRP) inhibitors represent a breakthrough class of targeted therapies developed primarily for the prevention and treatment of migraines. CGRP is a neuropeptide that plays a central role in migraine pathophysiology by mediating vasodilation and pain transmission in the nervous system. CGRP inhibitors work by either blocking the CGRP receptor or binding directly to the CGRP ligand, thereby reducing the frequency, severity, and duration of migraine attacks.

The CGRP inhibitors market includes monoclonal antibodies and small-molecule antagonists, commonly known as "gepants," delivered through injectable, oral, and intranasal routes of administration. These therapies are increasingly used for both episodic and chronic migraine patients who do not respond adequately to conventional treatments such as triptans, beta-blockers, or antidepressants. The scope of the market extends across hospitals, neurology clinics, retail pharmacies, and online pharmacies, with adoption supported by growing awareness, improving reimbursement frameworks, and expanding indications beyond migraine, including cluster headaches and post-traumatic headache disorders.

Market Growth Drivers:

The global CGRP inhibitors market is experiencing robust growth driven by the rising global burden of migraine disorders. Migraine is recognized as one of the leading causes of years lived with disability worldwide, affecting over one billion people globally. Increasing diagnosis rates, improved disease awareness, and recognition of migraine as a chronic neurological condition are significantly expanding the addressable patient population.

Another major growth driver is the strong clinical efficacy and safety profile demonstrated by CGRP inhibitors. Clinical trials and real-world evidence have consistently shown meaningful reductions in monthly migraine days and improvements in quality of life among patients receiving CGRP-targeted therapies. These outcomes have led to the inclusion of CGRP inhibitors in updated clinical guidelines, with leading neurological associations recognizing them as first-line preventive treatment options in appropriate patient populations.

Regulatory support has further accelerated market growth. Health authorities such as the U.S. FDA, European Medicines Agency (EMA), and regulatory bodies in Asia-Pacific have approved multiple CGRP inhibitors over the past few years, including newer oral and nasal formulations. Faster regulatory approvals and expanded indications have shortened time-to-market and increased physician confidence in prescribing these therapies.

Technological advancements and innovation in drug delivery formats also play a crucial role. The development of oral and intranasal CGRP inhibitors offers greater convenience, improved patient adherence, and broader accessibility compared to injectable biologics. Additionally, increasing integration of digital health tools, such as migraine tracking apps and tele-neurology platforms, supports early diagnosis, personalized treatment, and long-term disease management, indirectly boosting adoption of CGRP inhibitors.

Market Restraints:

Despite its strong growth outlook, the CGRP inhibitors market faces several challenges. One of the most significant restraints is the high cost of therapy, particularly for monoclonal antibody-based CGRP inhibitors. Premium pricing and long-term treatment requirements can limit accessibility, especially in low- and middle-income countries and in regions with strict reimbursement policies.

Reimbursement barriers and payer restrictions remain a concern in several healthcare systems. In some markets, CGRP inhibitors are still positioned as second- or third-line therapies, requiring patients to fail multiple conventional treatments before gaining access. These step-therapy requirements can delay treatment initiation and restrict market penetration.

Additionally, long-term safety concerns and limited real-world data over extended treatment durations may create hesitation among certain prescribers and patients. Although current evidence supports favorable safety profiles, ongoing post-marketing surveillance and long-term studies are necessary to fully establish risk-benefit outcomes, particularly for younger and comorbid patient populations.

Market Opportunities:

The CGRP inhibitors market presents significant opportunities driven by ongoing innovation, expanding indications, and geographic expansion. One of the most promising opportunities lies in the development of next-generation CGRP inhibitors with improved efficacy, longer dosing intervals, and enhanced safety profiles. Research into combination therapies and novel targets within migraine biology may further expand therapeutic options.

The growing demand for oral and non-injectable therapies represents another major opportunity. Small-molecule CGRP antagonists offer scalability, easier distribution, and lower manufacturing complexity compared to biologics, making them particularly attractive in emerging markets. As patents for first-generation CGRP inhibitors approach expiration, the introduction of biosimilars and generics is expected to improve affordability and patient access.

Emerging markets in Asia-Pacific, Latin America, and the Middle East & Africa offer untapped growth potential due to large undiagnosed populations, improving healthcare infrastructure, and rising awareness of neurological disorders. Strategic collaborations with local pharmaceutical companies, investment in physician education, and flexible pricing strategies will be critical for capturing these opportunities.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the global CGRP inhibitors market?
  • Which drug types, routes of administration, and treatment indications are shaping adoption trends?
  • How are regulatory approvals and clinical guideline updates influencing market dynamics?
  • Who are the key players in the CGRP inhibitors market, and what strategies are they using to strengthen their market position?
  • What are the emerging trends and long-term growth prospects across major regions?

Competitive Intelligence and Business Strategy:

The global CGRP inhibitors market is characterized by intense competition and rapid innovation. Leading pharmaceutical companies such as Amgen Inc., Eli Lilly and Company, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., and Lundbeck A/S focus heavily on research and development to expand their product pipelines and maintain competitive advantage. These players invest in clinical trials to explore new indications, improve formulations, and enhance delivery mechanisms.

Strategic partnerships, licensing agreements, and co-marketing collaborations are widely adopted to expand geographic reach and accelerate commercialization. Companies are also increasingly focusing on patient support programs, real-world evidence generation, and value-based pricing models to strengthen relationships with payers and healthcare providers. The anticipated entry of biosimilars is expected to intensify competition, prompting innovators to emphasize differentiation through innovation, brand loyalty, and lifecycle management strategies.

Key Companies Profiled:

  • Amgen Inc.
  • Eli Lilly and Company
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Lundbeck A/S
  • Biohaven Pharmaceutical Holding Company
  • Novartis AG
  • UCB Pharma
  • Alder BioPharmaceuticals

Key Segments Covered in CGRP Inhibitors Industry Research

By Drug Type

  • Monoclonal Antibodies
  • Small Molecule CGRP Antagonists

By Treatment Type

  • Preventive Migraine Treatment
  • Acute (Abortive) Treatment

By Route of Administration

  • Injectable
  • Oral
  • Nasal

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Gummy Vitamins Market Snapshot, 2025 and 2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. COVID-19 Impact Analysis
  • 2.4. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Value Chain Analysis
  • 3.2. Key Market Players
  • 3.3. Regulatory Landscape
  • 3.4. PESTLE Analysis
  • 3.5. Porter's Five Force Analysis
  • 3.6. Consumer Behavior Analysis

4. Price Trend Analysis, 2019 - 2032

  • 4.1. Pricing Analysis, By Product Type
  • 4.2. Key Factors Impacting Product Prices
  • 4.3. Regional Prices and Product Preferences

5. Global Gummy Vitamins Market Outlook

  • 5.1. Market Size (US$ Mn) Analysis and Forecast
    • 5.1.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
    • 5.1.2. Market Size (US$ Mn) Analysis and Forecast, 2025-2032
  • 5.2. Global Gummy Vitamins Market Outlook: Product Type
    • 5.2.1. Historical Market Size (US$ Mn) Analysis, By Product Type, 2019-2024
    • 5.2.2. Market Size (US$ Mn) Analysis and Forecast, By Product Type, 2025-2032
      • 5.2.2.1. Single Vitamin Gummies
      • 5.2.2.2. Multivitamin Gummies
  • 5.3. Market Attractiveness Analysis: Product Type
  • 5.4. Global Gummy Vitamins Market Outlook: Source
    • 5.4.1. Historical Market Size (US$ Mn) Analysis, By Source, 2019-2024
    • 5.4.2. Market Size (US$ Mn) Analysis and Forecast, By Source, 2025-2032
      • 5.4.2.1. Plant Based
      • 5.4.2.2. Animal Based
  • 5.5. Market Attractiveness Analysis: Source
  • 5.6. Global Gummy Vitamins Market Outlook: End User
    • 5.6.1. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2024
    • 5.6.2. Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
      • 5.6.2.1. Children
      • 5.6.2.2. Adults
  • 5.7. Market Attractiveness Analysis: End User
  • 5.8. Global Gummy Vitamins Market Outlook: Packaging Type
    • 5.8.1. Historical Market Size (US$ Mn) Analysis, By Packaging Type, 2019-2024
    • 5.8.2. Market Size (US$ Mn) Analysis and Forecast, By Packaging Type, 2025-2032
      • 5.8.2.1. Bottle & Jars
      • 5.8.2.2. Stand Up Pouches
      • 5.8.2.3. Others
  • 5.9. Market Attractiveness Analysis: Packaging Type
  • 5.10. Global Gummy Vitamins Market Outlook: Distribution Channel
    • 5.10.1. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2019-2024
    • 5.10.2. Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
      • 5.10.2.1. Hypermarkets/ Supermarkets
      • 5.10.2.2. Drug Stores & Pharmacies
      • 5.10.2.3. Convenience Stores
      • 5.10.2.4. Specialty Wellness Stores
      • 5.10.2.5. Online Retail
      • 5.10.2.6. Others
  • 5.11. Market Attractiveness Analysis: Distribution Channel

6. Global Gummy Vitamins Market Outlook: Region

  • 6.1. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
  • 6.2. Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
    • 6.2.1. North America
    • 6.2.2. Latin America
    • 6.2.3. Europe
    • 6.2.4. East Asia
    • 6.2.5. South Asia and Oceania
    • 6.2.6. Middle East & Africa
  • 6.3. Market Attractiveness Analysis: Region

7. North America Gummy Vitamins Market Outlook

  • 7.1. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 7.1.1. By Country
    • 7.1.2. By Product Type
    • 7.1.3. By Source
    • 7.1.4. By End User
    • 7.1.5. By Packaging Type
    • 7.1.6. By Distribution Channel
  • 7.2. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 7.2.1. U.S.
    • 7.2.2. Canada
  • 7.3. Market Size (US$ Mn) Analysis and Forecast, By Product Type, 2025-2032
    • 7.3.1. Single Vitamin Gummies
    • 7.3.2. Multivitamin Gummies
  • 7.4. Market Size (US$ Mn) Analysis and Forecast, By Source, 2025-2032
    • 7.4.1. Plant Based
    • 7.4.2. Animal Based
  • 7.5. Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 7.5.1. Children
    • 7.5.2. Adults
  • 7.6. Market Size (US$ Mn) Analysis and Forecast, By Packaging Type, 2025-2032
    • 7.6.1. Bottle & Jars
    • 7.6.2. Stand Up Pouches
    • 7.6.3. Others
  • 7.7. Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 7.7.1. Hypermarkets/ Supermarkets
    • 7.7.2. Drug Stores & Pharmacies
    • 7.7.3. Convenience Stores
    • 7.7.4. Specialty Wellness Stores
    • 7.7.5. Online Retail
    • 7.7.6. Others
  • 7.8. Market Attractiveness Analysis

8. Europe Gummy Vitamins Market Outlook

  • 8.1. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 8.1.1. By Country
    • 8.1.2. By Product Type
    • 8.1.3. By Source
    • 8.1.4. By End User
    • 8.1.5. By Packaging Type
    • 8.1.6. By Distribution Channel
  • 8.2. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 8.2.1. Germany
    • 8.2.2. France
    • 8.2.3. U.K.
    • 8.2.4. Italy
    • 8.2.5. Spain
    • 8.2.6. Russia
    • 8.2.7. Rest of Europe
  • 8.3. Market Size (US$ Mn) Analysis and Forecast, By Product Type, 2025-2032
    • 8.3.1. Single Vitamin Gummies
    • 8.3.2. Multivitamin Gummies
  • 8.4. Market Size (US$ Mn) Analysis and Forecast, By Source, 2025-2032
    • 8.4.1. Plant Based
    • 8.4.2. Animal Based
  • 8.5. Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 8.5.1. Children
    • 8.5.2. Adults
  • 8.6. Market Size (US$ Mn) Analysis and Forecast, By Packaging Type, 2025-2032
    • 8.6.1. Bottle & Jars
    • 8.6.2. Stand Up Pouches
    • 8.6.3. Others
  • 8.7. Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 8.7.1. Hypermarkets/ Supermarkets
    • 8.7.2. Drug Stores & Pharmacies
    • 8.7.3. Convenience Stores
    • 8.7.4. Specialty Wellness Stores
    • 8.7.5. Online Retail
    • 8.7.6. Others
  • 8.8. Market Attractiveness Analysis

9. East Asia Gummy Vitamins Market Outlook:

  • 9.1. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 9.1.1. By Country
    • 9.1.2. By Product Type
    • 9.1.3. By Source
    • 9.1.4. By End User
    • 9.1.5. By Packaging Type
    • 9.1.6. By Distribution Channel
  • 9.2. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 9.2.1. China
    • 9.2.2. Japan
    • 9.2.3. South Korea
  • 9.3. Market Size (US$ Mn) Analysis and Forecast, By Product Type, 2025-2032
    • 9.3.1. Single Vitamin Gummies
    • 9.3.2. Multivitamin Gummies
  • 9.4. Market Size (US$ Mn) Analysis and Forecast, By Source, 2025-2032
    • 9.4.1. Plant Based
    • 9.4.2. Animal Based
  • 9.5. Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 9.5.1. Children
    • 9.5.2. Adults
  • 9.6. Market Size (US$ Mn) Analysis and Forecast, By Packaging Type, 2025-2032
    • 9.6.1. Bottle & Jars
    • 9.6.2. Stand Up Pouches
    • 9.6.3. Others
  • 9.7. Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 9.7.1. Hypermarkets/ Supermarkets
    • 9.7.2. Drug Stores & Pharmacies
    • 9.7.3. Convenience Stores
    • 9.7.4. Specialty Wellness Stores
    • 9.7.5. Online Retail
    • 9.7.6. Others
  • 9.8. Market Attractiveness Analysis

10. South Asia & Oceania Gummy Vitamins Market Outlook:

  • 10.1. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 10.1.1. By Country
    • 10.1.2. By Product Type
    • 10.1.3. By Source
    • 10.1.4. By End User
    • 10.1.5. By Packaging Type
    • 10.1.6. By Distribution Channel
  • 10.2. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 10.2.1. India
    • 10.2.2. Indonesia
    • 10.2.3. Thailand
    • 10.2.4. Singapore
    • 10.2.5. ANZ
    • 10.2.6. Rest of South Asia & Oceania
  • 10.3. Market Size (US$ Mn) Analysis and Forecast, By Product Type, 2025-2032
    • 10.3.1. Single Vitamin Gummies
    • 10.3.2. Multivitamin Gummies
  • 10.4. Market Size (US$ Mn) Analysis and Forecast, By Source, 2025-2032
    • 10.4.1. Plant Based
    • 10.4.2. Animal Based
  • 10.5. Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 10.5.1. Children
    • 10.5.2. Adults
  • 10.6. Market Size (US$ Mn) Analysis and Forecast, By Packaging Type, 2025-2032
    • 10.6.1. Bottle & Jars
    • 10.6.2. Stand Up Pouches
    • 10.6.3. Others
  • 10.7. Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 10.7.1. Hypermarkets/ Supermarkets
    • 10.7.2. Drug Stores & Pharmacies
    • 10.7.3. Convenience Stores
    • 10.7.4. Specialty Wellness Stores
    • 10.7.5. Online Retail
    • 10.7.6. Others
  • 10.8. Market Attractiveness Analysis

11. Latin America Gummy Vitamins Market Outlook:

  • 11.1. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 11.1.1. By Country
    • 11.1.2. By Product Type
    • 11.1.3. By Source
    • 11.1.4. By End User
    • 11.1.5. By Packaging Type
    • 11.1.6. By Distribution Channel
  • 11.2. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 11.2.1. Brazil
    • 11.2.2. Mexico
    • 11.2.3. Rest of Latin America
  • 11.3. Market Size (US$ Mn) Analysis and Forecast, By Product Type, 2025-2032
    • 11.3.1. Single Vitamin Gummies
    • 11.3.2. Multivitamin Gummies
  • 11.4. Market Size (US$ Mn) Analysis and Forecast, By Source, 2025-2032
    • 11.4.1. Plant Based
    • 11.4.2. Animal Based
  • 11.5. Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 11.5.1. Children
    • 11.5.2. Adults
  • 11.6. Market Size (US$ Mn) Analysis and Forecast, By Packaging Type, 2025-2032
    • 11.6.1. Bottle & Jars
    • 11.6.2. Stand Up Pouches
    • 11.6.3. Others
  • 11.7. Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 11.7.1. Hypermarkets/ Supermarkets
    • 11.7.2. Drug Stores & Pharmacies
    • 11.7.3. Convenience Stores
    • 11.7.4. Specialty Wellness Stores
    • 11.7.5. Online Retail
    • 11.7.6. Others
  • 11.8. Market Attractiveness Analysis

12. Middle East & Africa Gummy Vitamins Market Outlook:

  • 12.1. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 12.1.1. By Country
    • 12.1.2. By Product Type
    • 12.1.3. By Source
    • 12.1.4. By End User
    • 12.1.5. By Packaging Type
    • 12.1.6. By Distribution Channel
  • 12.2. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 12.2.1. GCC Countries
    • 12.2.2. Egypt
    • 12.2.3. South Africa
    • 12.2.4. Northern Africa
    • 12.2.5. Rest of Middle East & Africa
  • 12.3. Market Size (US$ Mn) Analysis and Forecast, By Product Type, 2025-2032
    • 12.3.1. Single Vitamin Gummies
    • 12.3.2. Multivitamin Gummies
  • 12.4. Market Size (US$ Mn) Analysis and Forecast, By Source, 2025-2032
    • 12.4.1. Plant Based
    • 12.4.2. Animal Based
  • 12.5. Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 12.5.1. Children
    • 12.5.2. Adults
  • 12.6. Market Size (US$ Mn) Analysis and Forecast, By Packaging Type, 2025-2032
    • 12.6.1. Bottle & Jars
    • 12.6.2. Stand Up Pouches
    • 12.6.3. Others
  • 12.7. Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 12.7.1. Hypermarkets/ Supermarkets
    • 12.7.2. Drug Stores & Pharmacies
    • 12.7.3. Convenience Stores
    • 12.7.4. Specialty Wellness Stores
    • 12.7.5. Online Retail
    • 12.7.6. Others
  • 12.8. Market Attractiveness Analysis

13. Competition Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. Market Structure
    • 13.2.1. Competition Intensity Mapping By Market
    • 13.2.2. Competition Dashboard
  • 13.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 13.3.1. Nestle
      • 13.3.1.1. Overview
      • 13.3.1.2. Segments and Product Type
      • 13.3.1.3. Key Financials
      • 13.3.1.4. Market Developments
      • 13.3.1.5. Market Strategy
    • 13.3.2. Unilever
    • 13.3.3. Pfizer Inc.
    • 13.3.4. Amway
    • 13.3.5. Bayer AG
    • 13.3.6. Haleon plc
    • 13.3.7. Herbalife
    • 13.3.8. The Clorox Company
    • 13.3.9. Church & Dwight Co., Inc.
    • 13.3.10. Otsuka Pharmaceutical Co., Ltd.
    • 13.3.11. TopGum Industries Ltd.
    • 13.3.12. Santa Cruz Nutritionals
    • 13.3.13. Blackmores
    • 13.3.14. Novomins Nutrition
    • 13.3.15. ZanonVitamec
    • 13.3.16. Others

14. Appendix

  • 14.1. Research Methodology
  • 14.2. Research Assumptions
  • 14.3. Acronyms and Abbreviations